| Literature DB >> 35895664 |
Makoto Yoshida1, Tetsuya Hiramoto2, Atsushi Moriwaki1, Hisayuki Osoreda1, Tomoaki Iwanaga1, Hiromasa Inoue3.
Abstract
Physical activity, which can be affected by airflow limitation and extrapulmonary comorbidities, has been reported to be reduced in patients with chronic obstructive pulmonary disease, and reduced physical activity is associated with higher risks of exacerbation and mortality. The aim of the present study is to elucidate the comprehensive effect of extrapulmonary comorbidities on physical activity in Japanese patients with chronic obstructive pulmonary disease, of which evidence is lacking. We conducted a cross-sectional study with a series of tests, including lung function, physical activity, symptom scores, and parameters for comorbidities. Sixty outpatients with stable disease were enrolled, and the relationship between the parameters and physical activity was evaluated. Physical activity was assessed over 7 consecutive days using a triaxial accelerometer, which records total daily energy expenditure, step count, and walking time. Cardiovascular status was assessed via echocardiography, and pulmonary artery pressure was estimated using Doppler sonography. As to mental status, depression and anxiety were assessed using the Self-Rating Depression Scale and State-Trait Anxiety Inventory, respectively. Physical activity level was significantly correlated with step count, walking time, body mass index, lean body mass index, lung function, pulmonary artery pressure, depression, anxiety, and serum total cholesterol level. In a median regression model analysis, low lung function, low lean body mass index, depression, and low serum total cholesterol level were independently associated with decreased physical activity level. These findings suggest that physical inactivity is affected by multiple extrapulmonary factors, including skeletal muscle dysfunction, depressive symptoms, and nutritional state, in Japanese patients with chronic obstructive pulmonary disease.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35895664 PMCID: PMC9328493 DOI: 10.1371/journal.pone.0270836
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Mean values of demographic characteristics and pulmonary function by GOLD stages.
| Total | GOLD I | GOLD II | GOLD III | GOLD IV | P value | |
|---|---|---|---|---|---|---|
| Gender, male/female | 60 (52/8) | 15 (10/5) | 22 (19/3) | 13 (13/0) | 9 (9/0) | |
| Age (year) | 73.7 (7.0) | 72.8 (9.5) | 74.9 (5.8) | 75.0 (6.9) | 70.1 (4.8) | 0.222 |
| Height (cm) | 161.0 (6.6) | 161.5 (8.0) | 160.6 (6.8) | 159.1 (5.1) | 163.9 (5.7) | 0.400 |
| Weight (kg) | 57.2 (10.9) | 61.2 (11.8) | 59.3 (9.8) | 54.6 (11.3) | 49.9 (8.4) | 0.050 |
| Physical activity (Ex/day) | 1.38 (1.50) | 2.13 (1.56) | 1.60 (1.46) | 0.99 (1.50) | 0.15 (0.10) | <0.001 |
| Step count (/day) | 3293 (3002) | 4876 (2973) | 3687 (2954) | 2507 (3016) | 860 (785) | <0.001 |
| Walking time (min/day) | 52.2 (39.5) | 68.4 (35.1) | 58.7 (41.9) | 46.8 (39.1) | 16.8 (12.3) | 0.002 |
| BMI (kg/m2) | 20.1 (3.88) | 23.4 (4.22) | 22.9 (3.20) | 21.5 (3.92) | 18.6 (3.15) | 0.014 |
| LBMI (kg/m2) | 16.8 (2.09) | 17.4 (1.60) | 17.2 (1.81) | 16.4 (2.81) | 15.0 (1.33) | 0.020 |
| FVC (% predicted) | 95.7 (21.7) | 127.3 (12.8) | 95.8 (11.1) | 84.9 (15.4) | 68.6 (15.9) | <0.001 |
| FEV1 (% predicted) | 62.2 (27.7) | 99.3 (13.9) | 63.4 (9.52) | 47.6 (16.0) | 22.9 (5.35) | <0.001 |
| 68.1 (29.6) | 77.1 (19.6) | 75.9 (30.5) | 55.6 (33.6) | 51.1 (25.5) | 0.036 |
Values are given as the mean with standard deviations in brackets for continuous variables. A P value < 0.05 denotes statistical significance of the difference in each variable among GOLD stages.
GOLD, Global Initiative for Chronic Obstructive Lung Disease; BMI, body mass index; LBMI, lean body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity of lung for carbon monoxide natriuretic peptide.
Mean values of the parameters of extrapulmonary comorbidities by GOLD stages.
| Total | GOLD I | GOLD II | GOLD III | GOLD IV | P value | |
|---|---|---|---|---|---|---|
| LVEF (%) | 69.5 (6.13) | 69.3 (4.50) | 69.9 (7.29) | 69.3 (5.48) | 62.2 (7.07) | 0.985 |
| esPAP (mmHg) | 34.0 (8.85) | 32.8 (8.65) | 33.3 (8.74) | 34.0 (8.43) | 37.9 (10.41) | 0.550 |
| SDS | 38.9 (9.31) | 38.0 (9.37) | 36.2 (8.55) | 42.2 (10.6) | 42.9 (7.59) | 0.147 |
| STAI1 | 38.2 (9.89) | 40.5 (11.27) | 34.9 (7.42) | 38.9 (9.89) | 41.8 (12.0) | 0.204 |
| STAI2 | 39.0 (10.2) | 39.9 (11.27) | 36.9 (9.48) | 40.7 (10.0) | 41.9 (10.7) | 0.453 |
| NT-proBNP (pg/dL) | 151.2 (208.2) | 126.3 (152.5) | 172.0 (289.9) | 193.8 (145.4) | 78.3 (69.5) | 0.564 |
| Alb (g/dL) | 4.12 (0.37) | 4.09 (0.31) | 4.06 (0.41) | 4.20 (0.40) | 4.20 (0.32) | 0.645 |
| Hb (g/dL) | 14.2 (1.29) | 14.3 (1.28) | 14.0 (1.16) | 14.2 (1.70) | 14.5 (1.10) | 0.833 |
| TG (mg/dL) | 132.5 (81.6) | 133.4 (110.5) | 153.9 (87.9) | 115.5 (39.1) | 101.1 (36.8) | 0.330 |
| TC (mg/dL) | 190.9 (34.9) | 198.6 (38.6) | 193.9 (31.71) | 176.4 (32.9) | 191.4 (38.5) | 0.376 |
| LDL-C (mg/dL) | 102.2(29.2) | 107.6(26.1) | 107.4(30.2) | 85.8(24.9) | 103.9(32.9) | 0.143 |
| CRP (mg/dL) | 0.24 (0.34) | 0.13 (0.07) | 0.21 (0.21) | 0.36 (0.43) | 0.34 (0.61) | 0.224 |
| HbA1c (g/dL) | 5.84 (0.56) | 5.86 (0.51) | 5.78 (0.43) | 6.16 (0.78) | 5.5 (0.26) | 0.040 |
Values are given as the mean with standard deviations in brackets for continuous variables. A P value < 0.05 denotes statistical significance of the difference in each variable among GOLD stages.
GOLD, Global Initiative for Chronic Obstructive Lung Disease; LVEF, left ventricular ejection fraction; esPAP, estimated systolic pulmonary artery pressure; SDS, Self-Rating Depression Scale; STAI = State-Trait Anxiety Inventory; NT-proBNP, N-terminal pro-B-type natriuretic peptide; Alb = albumin; Hb, haemoglobin; TG, triglyceride; TC = total cholesterol; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; HbA1c, blood glycated haemoglobin
Relationship between physical activity and clinical characteristics assessed using Spearman’s rank correlation coefficient.
| r | P value | |
|---|---|---|
| Age (years) | -0.122 | 0.374 |
| Step count (/day) | 0.920 | <0.001 |
| Walk time (minutes/day) | 0.847 | <0.001 |
| BMI (kg/m2) | 0.376 | 0.006 |
| LBMI (kg/m2) | 0.495 | <0.001 |
| FVC (% predicted) | 0.540 | <0.001 |
| FEV1 (% predicted) | 0.657 | <0.001 |
| 0.514 | <0.001 | |
| LVEF (%) | 0.065 | 0.636 |
| esPAP (mmHg) | -0.320 | 0.017 |
| SDS | -0.457 | <0.001 |
| STAI1 | -0.287 | 0.034 |
| NT-proBNP (pg/dL) | -0.245 | 0.071 |
| Alb (g/dL) | 0.080 | 0.562 |
| TG (mg/dL) | 0.155 | 0.259 |
| TC (mg/dL) | 0.432 | 0.001 |
| LDL-C (mg/dL) | 0.341 | 0.012 |
| CRP (mg/dL) | -0.139 | 0.318 |
| HbA1c (g/dL) | 0.033 | 0.811 |
BMI, body mass index; LBMI = lean body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity of lung for carbon monoxide; LVEF, left ventricular ejection fraction; esPAP, estimated systolic pulmonary artery pressure; SDS, Self-Rating Depression Scale; STAI, State-Trait Anxiety Inventory; NT-proBNP, N-terminal pro-B-type natriuretic peptide; Alb, albumin; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; HbA1c, blood glycated haemoglobin. The p-value associated with a correlation is a test of the null hypothesis that the correlation equals zero.
Relationship between physical activity and clinical parameters assessed via multiple regression analysis.
| β | t | P value | |
|---|---|---|---|
| FEV1 (%predicted) | 0.494 | 5.80 | <0.001 |
| esPAP (mmHg) | -0.004 | -0.00 | 0.997 |
| LBMI (kg/m2) | 0.209 | 2.26 | 0.028 |
| SDS | -0.252 | -2.72 | 0.009 |
| TCho (mg/dL) | 0.280 | 3.12 | 0.003 |
Adjusted R2 = 0.621
FEV1, forced expiratory volume in 1 second; esPAP, estimated systolic pulmonary artery pressure; LBMI, lean body mass index; SDS, Self-Rating Depression Scale; TC, total cholesterol.